Marker Therapeutics Ownership
| MRKR Stock | USD 1.25 0.05 3.85% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Marker |
Marker Stock Ownership Analysis
About 42.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.87. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Marker Therapeutics recorded a loss per share of 1.07. The entity last dividend was issued on the 16th of September 2016. The firm had 1:10 split on the 27th of January 2023. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company was founded in 1999 and is headquartered in Houston, Texas. Marker Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To find out more about Marker Therapeutics contact Peter MBA at 713 400 6400 or learn more at https://markertherapeutics.com.Marker Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marker Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marker Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marker Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marker Therapeutics Outstanding Bonds
Marker Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Marker Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Marker bonds can be classified according to their maturity, which is the date when Marker Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MARKEL P 5 Corp BondUS570535AQ71 | View | |
| MARKEL P 35 Corp BondUS570535AR54 | View | |
| MARKEL P 43 Corp BondUS570535AS38 | View | |
| US570535AV66 Corp BondUS570535AV66 | View | |
| MKL 6 Corp BondUS570535AW40 | View |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.